Ophthalmic drugs, cancer cell therapies attract $340M+ on two HKEX biotech debuts
Nasdaq may be running the main biotech IPO show, but the Hong Kong stock exchange has some stellar performance on display even as the city …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
